Dr. Paner on HORIZON Trial in Multiple Myeloma

Video

Agne Paner, MD, director, discusses the phase II HORIZON trial in relapsed/refractory multiple myeloma.

Agne Paner, MD, director, Multiple Myeloma and Amyloidosis Program, Rush University Medical Center, discusses the phase II HORIZON trial in relapsed/refractory multiple myeloma.

Patients with relapsed/refractory multiple myeloma have an unmet medical need. Very few treatment options are available for those who are triple-refractory, says Paner; these patients are refractory to proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies. However, melflufen is a novel alkylator that is showing promise in this space.

In the ongoing phase II HORIZON trial (NCT02963493), patients with relapsed/refractory disease were treated with melflufen plus dexamethasone. Interim data showed an overall response rate of 28% with a clinical benefit rate of 40%, adds Paner. The median progression-free survival with the melflufen combination was 4 months with a median overall survival approaching close to 1 year, says Paner.

Thirty-six percent of patients had received 3 or more treatment regimens over the last 12 months. Furthermore, 91% of patients were classified as double-refractory, while 74% were determined to be triple class—refractory.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD